The issue focused on a letter submitted by the lawyer to the Department of Justice by the lawyer to the FDA, requesting a delay in action on a biotechnology company seeking approval for the use of its drug lysergic acid diethylamide (LSD). The FDA is investigating the company for filing applications to market the drug.


Last month, the FDA denied the agency's request to delay the agency's decision on the drug by a month or two or suspend the agency's review of the drug application